Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
2007-10-24
2010-11-02
Wilson, James O (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
C514S851000, C514S958000
Reexamination Certificate
active
07825095
ABSTRACT:
A patient suffering from an endobronchial infection is treated by administering to the patient for inhalation a dose of less than about 4.0 ml of a nebulized aerosol formulation comprising from about 60 to about 200 mg/ml of an aminoglycoside antibiotic, such as tobramycin, in a physiologically acceptable carrier in a time period of less than about 10 minutes. Unit dose devices for storage and delivery of the aminoglycoside antibiotic formulations are also provided.
REFERENCES:
patent: 5508269 (1996-04-01), Smith
patent: 5758637 (1998-06-01), Ivri
patent: 6083922 (2000-07-01), Montgomery
patent: 6387886 (2002-05-01), Montgomery
patent: 6890907 (2005-05-01), Speirs
patent: 9843650 (1998-10-01), None
patent: 0035461 (2000-06-01), None
patent: 0134232 (2001-05-01), None
Aerogen Inc. SEC Form 10-K, 2000.
* AeroGen's Annual Report 2000.
Coates, A.L, et al., “The Choice of Jet Nebulizer, Nebulizing Flow, and Addition of Albuterol Affects the Output of Tobramycin Aerosols,” Chest 111(5):1206-1212, 1997.
Cooney, G.F., et al., “Absolute Bioavailability and Absorption Characteristics of Aerosolized Tobramycin in Adults With Cystic Fibrosis,” Clin. Pharmacol. 34:255-259, 1994.
* Cystic L web page.
* De Young, L.R., et al., “The Aerodose Multidose Inhaler Device Design and Delivery Characteristics,” Proceedings of Respiratory Drug Delivery VI, Hilton Head, S.C., Apr. 1998, pp. 91-95.
Durrani, F.K., et al., “Evaluation of a New, Shorter Method of Administration of Adrenergic Aerosols in the Treatment of Asthma,” Annals of Allergy 61:147-150, 1988.
* Eisenberg, J., et al., “A Comparison of Peak Sputum Tobramycin Concentration in Patients With Cystic Fibrosis Using Jet and Ultrasonic Nebulizer Systems,” Chest 111(4):955-962, 1997.
Faurisson, F., et al., “Étude Comparative sur les Performances et l'Ergonomie de Nébuliseurs dans la Mucoviscidose,” Rev. Mal. Resp. 13:155-162, 1996.
Geller, D.E., et al., “Efficiency of Pulmonary Administration of Tobramycin Solution for Inhalation in Cystic Fibrosis Using an Improved Drug Delivery System,” Chest 123:28-36, 2003.
* Gopalakrishnan, V., and W. Xia, “Aerodose™ Inhaler: Effect of Formulation Physicochemical Properties on Aerosol Attributes,” Proceedings of Respiratory Drug Delivery VII, Tarpon Springs, Fla., May 14-18, 2000, pp. 299-301.
* Gopalakrishnan,V., et al., “Aerodose™ Inhaler: Comparison of In Vitro Particle Size Data, Computer Modeled and Scintigraphic Lung Deposition Profiles,” Proceedings of Respiratory Drug Delivery VII, Tarpon Springs, Fla., May 14-18, 2000, pp. 303-306.
Ho, S.L., and A.L. Coates, “Effect of Dead Volume on the Efficiency and the Cost to Deliver Medications in Cystic Fibrosis With Four Disposable Nebulizers,” Can. Respir. J. 6(3):253-260, 1999.
* Hüls, G., et al., “Pilot Study on Toleration of Inhalation With a New High Concentrated Tobramycin Solution Using an Improved Nebulizer,” Netherlands Journal of Medicine 54:S37-S38, 1999.
Kendrick, A.H., et al., “Selecting and Using Nebuliser Equipment,” Thorax 52(Suppl 2):S92-S101, 1997.
* Le Brun, P.P.H., et al., “Inhalation of Tobramycin in Cystic Fibrosis / Part 2: Optimization of the Tobramycin Solution for a Jet and an Ultrasonic Nebulizer,” International Journal of Pharmaceutics 189:215-225, 1999.
Le Conte, P., et al., “Lung Distribution and Pharmacokinetics of Aerosolized Tobramycin,” Am. Rev. Respir. Dis. 147:1279-1282, 1993.
Littlewood, J.M. et al., “Aerosol Antibiotic Treatment in Cystic Fibrosis,” Archives of Disease in Childhood 68:788-792, 1993.
* Luangkhot, N., et al., “Characterisation of Salbutamol Solution Compared to Budesonide Suspensions Consisting of Submicron and Micrometer Particles in the PARI LC STAR and a New PARI Electronic Nebuliser (e-FLOW),” Proceedings of Drug Delivery to the Lungs XI, London, Dec. 11-12, 2000.
MacLusky, I.B., et al., “Long-Term Effects of Inhaled Tobramycin in Patients With Cystic Fibrosis Colonized With Pseudomonas aeruginosa,” Pediatric Pulmonology 7:42-48, 1989.
Makhoul, I. R., et al., “Antibiotic Treatment of Experimental Pseudomonas aeruginosa Pneumonia in Guinea Pigs: Comparison of Aerosol and Systemic Administration,” J. Infectious Diseases 168:1296-1299, 1993.
Nikolaizik, W.H., et al., “Bronchial Constriction After Nebulized Tobramycin Preparations and Saline in Patients With Cystic Fibrosis,” Eur. J. Pediatrics 155:608-611, 1996.
* Notice of Opposition, related EP Patent No. 1 320 355, Jan. 5, 2007.
* Pathogenesis Annual Report of 1999.
* “PathoGenesis Begins Clinical Trial of TOBI and AeroGen's Hand-Held AeroDose™ Inhaler,” PR Newswire, Jul. 11, 2000, <http://www.prnewswire.com> [retrieved Nov. 24, 2006].
“PathoGenesis Inks Deal With AeroGen,” Puget Sound Business Journal, © 2000 American City Business Journals Inc., <http://seattle.bizjournals.com/seattle/stories/2000/02/daily15.html> [retrieved Apr. 15, 2004].
Pathogenesis Corporation SEC Form 10-K, 1999.
Ramsey, B.W., et al., “Efficacy of Aerosolized Tobramycin in Patients With Cystic Fibrosis,”New England J. Med. 328:1740-1746, 1993.
* Ramsey, B.W., et al., “Intermittent Administration of Inhaled Tobramycin in Patients With Cystic Fibrosis,” New England J. Med. 340(1):23-30, 1999.
* Seitz, D.J., et al., “Stability of Tobramycin Sulfate in Plastic Syringes,” American Journal of Health System Pharmacy 37:1614-1615, 1980.
* Simon, M., and V. Gopalakrishnan, “Aerodose™ Inhaler-Aerosol Characteristics of a Systemic and a Respiratory Drug,” Proceedings of Respiratory Drug Delivery VII, Tarpon Springs, Fla., May 14-18, 2000, pp. 307-309.
Smith, A.L., et al., “Safety of Aerosol Tobramycin Administration for 3 Months to Patients With Cystic Fibrosis,” Pediatric Pulmonology 7:265-271, 1989.
Standaert, T.A., et al., “The Choice of Compressor Effects the Aerosol Parameters and the Delivery of Tobramycin From a Single Model Nebulizer,” J. Aerosol Medicine 13(2):147-153, 2000.
* Stangl, R., et al., “Characterising the First Prototype of a Vibrating Membrane Nebuliser,” Proceedings of Respiratory Drug Delivery VII, Tarpon Springs, Fla., May 2000.
* Stangl, R., et al., “Characterising the Functional Model of a Vibrating Membrane Nebuliser,” Proceedings of Drug Delivery to the Lungs X, London, Dec. 2-3, 1999, pp. 1-4.
* Stangl, R., et al., “Estimating the Efficiency of a Vibrating Membrane Nebuliser,” Proceedings of Drug Delivery to the Lungs XI, London, Dec. 11-12, 2000.
Steinkamp, G., et al., “Long-Term Tobramycin Aerosol Therapy in Cystic Fibrosis,” Pediatric Pulmonology 6:91-98, 1989.
“TOBI® Tobramycin Solution for Inhalation,” Prescribing Information, CHIRON Corporation, Emeryville, Calif., Apr. 2001, 4 pp.
* TOBI Package Insert.
Touw, D.J., et al., “Pharmacokinetics of Aerosolized Tobramycin in Adult Patients With Cystic Fibrosis,” Antimicrobial Agents and Chemotherapy 41:184-187, 1997.
Valcke, Y.J., and R.A. Pauwels, “Pharmocokinetic Evaluation of Tobramycin in the Alveolar Lining Fluid of the Rat After Endotracheal Administration,” Am. Rev. Respir. Dis. 144:1199-1201, 1991.
* Webb, A.K., and M.E. Dodd, “Nebulised Antibiotics for Adults With Cystic Fibrosis,” Thorax 57(Suppl. 2):S69-S71, 1997.
* Weber, A., et al., “Effect of Nebulizer Type and Antibiotic Concentration on Device Performance,” Pediatric Pulmonology 23:249-260, 1997.
Weber, A., et al., “Nebulizer Delivery of Tobramycin to the Lower Respiratory Tract,” Pediatric Pulmonology 17:331-339, 1994.
Weber, A., et al., “Tobramycin Serum Concentrations After Aerosol and Oral Administration in Cystic Fibrosis,” Am. J. Therapeutic
Challoner Peter Bruce
Schaeffler Barbara Ann
Speirs Robert John
McAvoy Cozette M
Novartis Vaccines and Diagnostics Inc.
Sackey Ebenezer
Wilson James O
LandOfFree
Methods and unit dose formulations for the inhalation... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods and unit dose formulations for the inhalation..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods and unit dose formulations for the inhalation... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4207558